DEF: Zymeworks Sets Annual Meeting Agenda

Zymeworks Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for December 15, 2026, detailing key proposals including director elections, executive compensation votes, and a new employee stock purchase plan.

Summary

• Zymeworks Inc. is holding its 2026 Annual Meeting of Stockholders virtually on December 15, 2026.
• Key proposals include the election of three Class II directors, an advisory vote on executive compensation, and the frequency of future advisory votes.
• Stockholders will also vote on the approval of the 2026 Employee Stock Purchase Plan and the declassification of the board of directors.
• The appointment of KPMG LLP as auditors for the year ending December 31, 2026, will be ratified.
• The meeting will be conducted virtually, with details on how to attend and vote provided.
• The record date for stockholders entitled to vote is October 21, 2026.
• The filing also includes detailed information on corporate governance, executive and director compensation, and share ownership as of October 21, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the company's proactive approach to corporate governance and employee benefits, alongside a clear plan for future meetings and proposals.

Positives

• Proactive scheduling of the 2026 Annual Meeting of Stockholders well in advance.
• Clear agenda with six distinct proposals for stockholder consideration.
• Proposal to declassify the board of directors, which is generally favored by investors for increased accountability.
• Introduction of a new 2026 Employee Stock Purchase Plan to incentivize employees.
• Detailed disclosures on corporate governance, executive compensation, and share ownership, promoting transparency.
• The company's say-on-pay vote in 2025 received strong support (94.06%), indicating general stockholder satisfaction with executive compensation practices.

Negatives

• The proposed amendment to declassify the board requires a 66 2/3% supermajority vote, which can be challenging to achieve.
• Oleg Nodelman, a director nominee, and EcoR1 Capital LLC were fined by French financial markets authority for market abuse violations, though they are appealing the decision.

Risks

• The declassification of the board requires a significant supermajority vote (66 2/3%), which may be difficult to attain.
• Potential for contested director elections if any proposals are met with significant opposition.
• The company's financial performance and ability to secure future financing or partnerships, as alluded to in the bonus achievement section, could impact future outlook.

Future Outlook

The filing outlines the agenda for the upcoming annual meeting, including proposals that will shape the company's future governance and employee incentive structures. The approval of the 2026 Employee Stock Purchase Plan and the declassification of the board are key forward-looking items.

Management Comments

• Stockholders are encouraged to read the proxy statement and promptly vote their shares.
• The Board of Directors believes that Mr. Galbraith's combined role of Chair and Chief Executive Officer enables strong leadership, creates clear accountability, and enhances the ability to communicate the company's message and strategy clearly and consistently to stockholders.
• The Board of Directors recommends voting FOR all nominees, FOR the advisory vote on executive compensation, 1 YEAR for the frequency of advisory votes, FOR the 2026 Employee Stock Purchase Plan, FOR the declassification of the board, and FOR the ratification of KPMG as auditors.

Industry Context

StockSavvy.ai notes that Zymeworks' proposals, particularly the declassification of the board and the employee stock purchase plan, align with current trends in corporate governance and executive compensation within the biotechnology sector, where attracting and retaining talent is crucial.

Comparison to Industry Standards

• The company's peer group for executive compensation benchmarking includes North American biotechnology companies of similar size and development stage, such as Alector, Inc., IGM Biosciences, Inc., and Xencor.
• The proposed declassification of the board is a common move among public companies seeking to enhance shareholder accountability, moving away from staggered boards which are less prevalent in the industry.
• The 2026 Employee Stock Purchase Plan, with 2,000,000 shares reserved, represents approximately 2.84% of outstanding shares as of October 21, 2026, which is a typical allocation for such plans in the sector.

Corporate Governance

Legal Proceedings

• Oleg Nodelman and EcoR1 Capital LLC were fined by the Enforcement Committee of the Autorit des Marchs Financiers (AMF) for violations of market abuse regulations and failures to comply with reporting obligations. Mr. Nodelman and the Fund have appealed the ruling.

Related Party Transactions

• On December 28, 2023, EcoR1 purchased $50 million in pre-funded warrants, with an agreement for EcoR1 to nominate a director. Oleg Nodelman (manager of EcoR1) is a director.
• On June 26, 2025, an amendment to EcoR1's pre-funded warrants removed an exercise limitation. Oleg Nodelman and Scott Platshon (a partner at EcoR1) were directors at the time.
• On August 10, 2025, Gregory A. Ciongoli (a director) purchased 415,000 shares for $5.0 million.
• Scott Platshon, a former director, entered into an employment agreement as Acting Chief Investment Officer and later Executive Vice President and Chief Business Officer, with associated stock options and RSUs.

Stakeholder Impact

• Shareholders: Voting on director elections, executive compensation, stock purchase plan, and board declassification directly impacts their influence and potential returns.
• Employees: The 2026 Employee Stock Purchase Plan offers a new opportunity for employees to acquire company stock, potentially increasing engagement and aligning interests.
• Directors and Officers: Subject to election, compensation review, and stock ownership guidelines, with potential implications from related party transactions and legal proceedings involving a director.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on December 15, 2026.
• Implementation of the 2026 Employee Stock Purchase Plan if approved.
• Phasing out of the classified board structure if Proposal 5 is approved, with full declassification by the 2029 annual meeting.
• The company will announce preliminary voting results at the Meeting and publish final results in a Form 8-K.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, outlining standard corporate governance and compensation proposals. While the declassification of the board and the ESPP are positive steps, there are no significant new financial results or strategic shifts that would warrant a buy or sell recommendation based solely on this document. The ongoing legal matter involving a director nominee introduces a minor note of caution.

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Employee Stock Purchase Plan, Corporate Governance, Board Declassification, Auditor Ratification